All posts

Follow Us

LinkedInInstagramX
Quarterly ResultsArchiveLast updated 11 November 20262 min read

Lotus Eye Hospital (LOTUSEYE) Q2 FY27 Profit Dips 28% Despite Strong Revenue Growth

Revenue jumped 36% year-on-year, but a sharp sequential drop in profit highlights the cost pressures from the company's ongoing expansion.

By Abhinav Singhvi, Founder & CEO Hexawealth · Created 11 November 2026

Lotus Eye Hospital posted robust revenue growth of 35.9% YoY in Q2 FY27, yet net profit fell 27.9% sequentially. The squeeze came from rising interest and depreciation costs linked to new capacity additions.

For Lotus Eye Hospital, the September quarter was a story of two speeds. The top line continued its strong run, but the bottom line stumbled under the weight of a deliberate, capital-heavy expansion strategy.

Revenue reached ₹17.72 crore, up 35.9% from a year ago and 3.9% from the previous quarter. Net profit, however, fell to ₹0.44 crore, a 27.9% drop sequentially even as it showed a large year-on-year improvement from a low base. The net profit margin compressed by 110 basis points from Q1.

Revenue & profit

Revenue (₹ Cr)

Net Profit (₹ Cr)

Revenue & profitQ2 FY26 (Sep 2025) 13.04, Q3 FY26 (Dec 2025) 13.55, Q4 FY26 (Mar 2026) 13.61, Q1 FY27 (Jun 2026) 17.06, Q2 FY27 (Sep 2026) 17.72. Q2 FY26 (Sep 2025) 0.12, Q3 FY26 (Dec 2025) -0.26, Q4 FY26 (Mar 2026) -0.32, Q1 FY27 (Jun 2026) 0.61, Q2 FY27 (Sep 2026) 0.44-20-1001020Q2 '26Q3 '26Q4 '26Q1 '27Q2 '27
  • Revenue (₹ Cr), Q2 FY26 (Sep 2025): 13.04
  • Revenue (₹ Cr), Q3 FY26 (Dec 2025): 13.55
  • Revenue (₹ Cr), Q4 FY26 (Mar 2026): 13.61
  • Revenue (₹ Cr), Q1 FY27 (Jun 2026): 17.06
  • Revenue (₹ Cr), Q2 FY27 (Sep 2026): 17.72
  • Net Profit (₹ Cr), Q2 FY26 (Sep 2025): 0.12
  • Net Profit (₹ Cr), Q3 FY26 (Dec 2025): -0.26
  • Net Profit (₹ Cr), Q4 FY26 (Mar 2026): -0.32
  • Net Profit (₹ Cr), Q1 FY27 (Jun 2026): 0.61
  • Net Profit (₹ Cr), Q2 FY27 (Sep 2026): 0.44

Revenue (₹ Cr)

Revenue (₹ Cr)Q2 FY26 (Sep 2025) 13.04, Q3 FY26 (Dec 2025) 13.55, Q4 FY26 (Mar 2026) 13.61, Q1 FY27 (Jun 2026) 17.06, Q2 FY27 (Sep 2026) 17.7205101520Q2 '26Q3 '26Q4 '26Q1 '27Q2 '27
  • Revenue (₹ Cr), Q2 FY26 (Sep 2025): 13.04
  • Revenue (₹ Cr), Q3 FY26 (Dec 2025): 13.55
  • Revenue (₹ Cr), Q4 FY26 (Mar 2026): 13.61
  • Revenue (₹ Cr), Q1 FY27 (Jun 2026): 17.06
  • Revenue (₹ Cr), Q2 FY27 (Sep 2026): 17.72

Net Profit (₹ Cr)

Net Profit (₹ Cr)Q2 FY26 (Sep 2025) 0.12, Q3 FY26 (Dec 2025) -0.26, Q4 FY26 (Mar 2026) -0.32, Q1 FY27 (Jun 2026) 0.61, Q2 FY27 (Sep 2026) 0.44-2-1012Q2 '26Q3 '26Q4 '26Q1 '27Q2 '27
  • Net Profit (₹ Cr), Q2 FY26 (Sep 2025): 0.12
  • Net Profit (₹ Cr), Q3 FY26 (Dec 2025): -0.26
  • Net Profit (₹ Cr), Q4 FY26 (Mar 2026): -0.32
  • Net Profit (₹ Cr), Q1 FY27 (Jun 2026): 0.61
  • Net Profit (₹ Cr), Q2 FY27 (Sep 2026): 0.44
MetricCurrentQ2 FY27 (Sep 2026)PreviousQ1 FY27 (Jun 2026)
Revenue (₹ Cr)
17.72
17.06
Net Profit (₹ Cr)
0.44
0.61
PAT Margin (%)
2.5
3.6

The Expansion Bill Comes Due

The profit squeeze is directly tied to funding growth. Interest expense surged 374.5% year-on-year and 17% quarter-on-quarter. Depreciation more than doubled from last year.

This combination, noted in a Univest preview, is consistent with debt-funded capacity additions now contributing to revenue but also to the cost structure. Management is prioritizing scale, with a new branch opened in Erode, Tamil Nadu, as reported by ALFA News.

A Volatile Path to Scale

Profitability has been volatile as the company invests. The trailing twelve-month net profit margin stands at a thin 0.8%. A StockFin.ai analysis states management is focused on expanding clinical capabilities and technology while strengthening cost control.

Live Chart

· LOTUSEYE

(BSE)

ISIN: INE947I01017

The near-term outlook hinges on how quickly new centres can ramp up patient volumes to offset their fixed costs. The company trades at a significant discount to the industry average P/E, reflecting the market's caution on this margin recovery timeline.

Key Points

  • Revenue growth remained healthy at 35.9% YoY, sustaining the momentum from the previous quarter.
  • Sequential profit declined 27.9% as interest and depreciation costs rose sharply due to expansion.
  • Management's strategy prioritizes geographic and technological scale over near-term margins.
  • The stock rose 6.5% on results day, suggesting the market viewed the revenue growth positively against a lack of analyst estimates.

Hexa Perspective

The quarter confirms Lotus Eye is in a classic growth-investment phase. The revenue engine is working, but the full benefit of new capacity is still ahead. The critical watchpoint is operating leverage: can patient volumes grow fast enough to outpace the rising fixed costs of depreciation and interest?

With negligible institutional ownership and a steady promoter stake, the stock's move will be driven by evidence of this margin inflection. For now, the story is one of promising top-line expansion awaiting a more profitable bottom line.

Share or follow HexaWealth

Also read

Want this applied to your portfolio?

Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.

Lotus Eye Hospital And Institute (LOTUSEYE) Q2 FY27 results, revenue and profits.

Frequently asked questions

What were Lotus Eye Hospital's Q2 FY27 results?
Lotus Eye Hospital reported revenue of ₹17.72 crore and a net profit of ₹0.44 crore for the quarter ended September 2026. Revenue grew 35.9% year-on-year, while profit declined 27.9% compared to the previous quarter (Q1 FY27).
Why did Lotus Eye Hospital's Q2 profit decline despite higher sales?
Profit fell 27.9% quarter-on-quarter because operating costs rose faster than revenue. Interest expense jumped 17% and depreciation increased 4% sequentially, costs linked to the company's debt-funded expansion into new centres, as noted by Univest.
What caused the margin pressure for Lotus Eye Hospital in Q2 FY27?
The net profit margin fell 110 basis points sequentially to 2.5%, pressured by a sharp rise in fixed costs. Interest cost surged 374.5% year-on-year and depreciation more than doubled, consistent with new capacity additions now on the books.
Why did interest expense surge for Lotus Eye Hospital in Q2 FY27?
Interest expense rose 374.5% year-on-year to ₹0.59 crore, driven by increased borrowing to fund the company's expansion. A Univest report links this to debt taken on for new capacity, which also began contributing to revenue growth.
What is Lotus Eye Hospital's management outlook for future profitability?
According to a StockFin.ai analysis, management has indicated plans to expand clinical capabilities, adopt technology, and strengthen cost control to improve future profitability. They are currently prioritizing scale over margins amid expansion costs.
What are Lotus Eye Hospital's expansion plans for FY27?
The company is in a growth phase, opening new centres like one in Erode, Tamil Nadu, as reported by ALFA News. Management is focusing on geographic expansion and technology investment, though this is currently pressuring profitability.
Did Lotus Eye Hospital's Q2 FY27 results beat analyst estimates?
No verified analyst estimates were publicly available for comparison, as noted in a Univest preview. The market reaction was positive, with the stock rising 6.5% on the results day, focusing on the strong year-on-year revenue growth.
How did Lotus Eye Hospital's stock react to the Q2 FY27 results?
The stock closed at ₹106.56 on November 11, 2026, up 6.51% from the previous close of ₹100.05, according to data from The Economic Times. Investors reacted positively to the sustained revenue growth.
Are mutual funds or FIIs increasing their stake in Lotus Eye Hospital?
Institutional holding remains negligible. As per a StockFin.ai analysis, FII and DII holdings were at 0% and 0.02% respectively in Q2 FY27. Promoter holding has remained steady at around 40.1%.
Lotus Eye Hospital Q2 profit drop
Lotus Eye Hospital's Q2 FY27 net profit was ₹0.44 crore, a drop of 27.9% from the ₹0.61 crore profit in Q1 FY27. The decline was due to rising interest and depreciation costs from the company's expansion activities.
Lotus Eye Hospital Q2 FY27 results order book
The reported results do not include an order book figure. For a hospital services company like Lotus Eye, key metrics are patient volumes and revenue per procedure, which showed strong year-on-year growth of 35.9% in Q2 FY27.